Conditions: Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour
Interventions: Drug: Octreotide; Drug: Octreotide; Drug: 177Lu-DOTA0-Tyr3-Octreotate
Sponsors: Advanced Accelerator Applications; Advanced Accelerator Applications; Pierrel Research Europe GmbH
Not yet recruiting - verified April 2012
Feeds
4628 items (4628 unread) in 80 feeds
Acinar Cell Carcinoma
(29 unread)
Acinic Cell Carcinoma
(33 unread)
Adenoid Cystic Carcinoma
(57 unread)
Adrenal Gland Cancer
(335 unread)
Ampulla Of Vater
(14 unread)
Anal Cancer
(252 unread)
Angiosarcoma
(73 unread)
Appendix Cancer
(35 unread)
Bile Duct Cancer
(386 unread)
Brain and CNS
(1151 unread)
Carcinoid
(143 unread)
Endocrine/Neuroendocrine
(291 unread)
Gall Bladder Cancer
(227 unread)
Hemangioendothelioma
(23 unread)
Hepatoblastoma
(31 unread)
Pancreas
(45 unread)
Phyllodes
(21 unread)
PMP and Mucinous Tumors
(19 unread)
Rhabdomyosarcoma
(191 unread)
Sarcoma
(602 unread)
Twitter Pals
(670 unread)
Trials - Carcinoid (6 unread)
-
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Posted: April 10th, 2012, 8:00am MDT
-
Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.
Posted: July 19th, 2011, 8:00am MDT
Conditions: Carcinoma; Carcinoma, Renal Cell; Neuroendocrine Tumors; Carcinoid Tumor; Pancreatic Islet Cell Tumors
Intervention: Other: Blood sampling by vena punction.
Sponsors: University Medical Centre Groningen; University Medical Centre Groningen
Completed - verified May 2012 -
Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
Posted: April 12th, 2010, 8:00am MDT
Condition: Symptoms of Carcinoid Syndrome
Interventions: Drug: Low Dose LX1606 - Day 1 (start); Drug: Mid-low dose LX1606 - Day 15 (start); Drug: Mid-high dose LX1606 - Day 29 (start); Drug: High dose LX1606 - Day 43 (start); Drug: 4-Week Open Label Dose Extension; Drug: 72-Week Open Label Dose Extension
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Active, not recruiting - verified May 2012 -
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
Posted: January 13th, 2010, 8:00am MST
Conditions: Adrenocortical Carcinoma; Gastrointestinal Carcinoid Tumor; Kidney Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: Seneca Valley virus-001; Drug: cyclophosphamide; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 -
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Posted: April 25th, 2007, 8:00am MDT
Conditions: Head and Neck Cancer; Islet Cell Tumor; Metastatic Cancer; Pheochromocytoma
Interventions: Drug: octreotide acetate; Radiation: yttrium Y 90 resin microspheres
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Terminated - verified May 2012 -
UCN-01 and Irinotecan in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple-Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Posted: March 8th, 2002, 8:00am MST
Condition: Cancer
Interventions: Drug: 7-hydroxystaurosporine; Drug: irinotecan hydrochloride; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); University of Virginia; National Cancer Institute (NCI); Washington University Siteman Cancer Center
Completed - verified August 2009